Table 2.

MRI measurements at baseline of patients entered into the lenercept MS trial

VariablePlacebo, n = 44Lenercept, mg
10, n = 4450, n = 40100, n = 40
Newly active lesions, mean Median (range)1.8 0 (0–16)1.5 0 (0–55)2.1 1 (0–11)1.9 1 (0–14)
Persistently active lesions, mean Median (range)1.2 0 (0–15)0.5 0 (0–6)1.6 0 (0–22)0.6 0 (0–7)
Burden of disease, mean Median (range)2,459.9 1,626.0 (26.2–9,888.7)2,236.2 1,147.4 (0–14,377.4)3,757.2 2,142.4 (67.3–16,319.0)2,707.2 1,365.3 (58.7–10,884.8)